Program
palbociclib
Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.
Drug pagePalbociclib: every studyMany companies study it; this page follows only the 35 they lead. All 225 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 291 open or running | phase 4since Jan 22, 2016 | Aug 30, 2005 | Dec 31, 2029phase 2 · NCT05226871 |
| biotx.aiits history only | 10 open or running | phase 2since Apr 26, 2022 | Apr 26, 2022 | none ahead |
| Criteriumits history only | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 1since Apr 16, 2025 | Apr 16, 2025 | Oct 2027phase 1 · NCT06941142 |
| iOMEDICOits history only | 10 open or running | phase 2since Aug 25, 2016 | Aug 25, 2016 | none ahead |
| Megalabsits history only | 10 open or running | phase 4since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Merck | 11 open or running | phase 2since Jul 18, 2022 | Jul 18, 2022 | Dec 22, 2026phase 2 · NCT05468697 |
Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2022First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT05468697 · 60 enrolled · United States, Australia, Israel
Ahead
- Dec 22, 2026Primary completion: phase 2 study in Carcinoma, Renal CellNCT05468697
TargetBeta
“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05468697Carcinoma, Renal Cell · United States, Australia, Israel | 2 | Active, not recruiting | Dec 22, 2026 | 60 |
How it is read
Names in the registry
- “Palbociclib”, 16 entries
- “PD-0332991”, 12 entries
- “palbociclib”, 5 entries
- “Palbociclib 125mg”, 3 entries
- “Palbociclib alone”, 3 entries
Codes read as this program: PD0332991.
Conditions, from the studies’ own filings
- Breast Neoplasms, 13 studies
- Carcinoma, Renal Cell, 1 study
- Sarcoma, Ewing, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.